Company: BLLN
Filing Date: 2025-09-17
Form Type: DRS/A
Source: 0001193125-25-206347
Chunk: 3

Company: BillionToOne, Inc.
Filing Date: 2025-09-17
Form: DRS/A
Chunk 3
---
 the section titled “Underwriting” for a description of the compensation payable to the underwriters. |

At our request, the underwriters have reserved up to 5% of the shares of Class A common stock being offered by this prospectus for sale, at the initial public offering price, to our officers, directors and employees through a directed share program. See the section titled “Underwriting – Directed share program.” We have granted the underwriters an option for a period of 30 days to purchase up to additional shares of Class A common stock. Investing in our Class A common stock involves a high degree of risk. See “ Risk factors” beginning on page 20. Neither the Securities and Exchange Commission nor any other state securities commission has approved or disapproved of these securities or passed on the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense. The underwriters expect to deliver the shares to purchasers on or about , 2025.

| J.P. Morgan |     | Piper Sandler          |     | Jefferies |     | William Blair |
| Stifel      |     | Wells Fargo Securities |     |           |     | BTIG          |

, 2025

BILLION TOONE We strive to remove the fear of the unknown. Our revolutionary technology allows us to push beyond the current limitations in diagnostics so we can detect disease one molecule at a time. We provide patients with powerful and precise information about the state of their health for themselves and their children. And it's only the beginning of what we seek to do.

Key Metrics $265M+ annualized revenue run-rate (ARR)1 86% YOY revenue growth2 Emerging profitability3 $100B US annual market opportunity4 REVENUE $209M LTM revenue5 167% CAGR (2021-2024) TESTS ACCESSIONED6 508K LTM tests accessioned as of Jun 30, 2025 51% YOY tests accessioned growth2 1M+ tests accessioned since launch GROSS PROFIT MARGIN 65% gross profit margin H1 2025 14 pp YOY increase in gross profit margin2 OTHER $1.8M ARR per sales representative 225M+ covered lives7 1. Q2 2025 revenue of $66.6M annualized. Calculated as Q2 2025 revenue multiplied by 4. 2. Q2 2025 over Q2 2024.